Ambrisentan
An endothelin receptor antagonist that blocks endothelin-1, a potent constrictor of blood vessels in the lungs, used to treat pulmonary arterial hypertension (PAH) by relaxing and widening the pulmonary arteries. It improves exercise capacity and slows disease progression in patients with PAH, reducing the strain on the right side of the heart.
Peso molecular
378,4000 g/mol
LogP
3,80
TPSA
81,50 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estructura 2D
Cite this structure
Embed this structure
SMILES
COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O
InChI
InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
Molecular Formula
C22H22N2O4
HBD / HBA
1 / 6
Enlaces Rotables
7
Átomos Pesados
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
An endothelin receptor antagonist that blocks endothelin-1, a potent constrictor of blood vessels in the lungs, used to treat pulmonary arterial hypertension (PAH) by relaxing and widening the pulmonary arteries. It improves exercise capacity and slows disease progression in patients with PAH, reducing the strain on the right side of the heart.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Ambrisentan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1111. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6918493. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ambrisentan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ambrisentan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ambrisentan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ambrisentan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ambrisentan"></drugfyi-drug>